Trials / Active Not Recruiting
Active Not RecruitingNCT05824325
Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancer（GALAXY）
Different Targeted Antibody-drug Conjugates for HER2 Ultra-low or no Expression Advanced Breast Cancer: a Phase Ⅰb/Ⅱ Study（GALAXY）
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 56 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a phaseⅠb/Ⅱ, open-label, two-arm parallel study evaluating the efficacy and safety of different targeted antibody-drug conjugates for HER2 ultra-low or no expression advanced breast cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-A1811 | HER2 ADC |
| DRUG | TROP2 ADC | TROP2 ADC |
Timeline
- Start date
- 2023-03-14
- Primary completion
- 2025-04-10
- Completion
- 2026-10-10
- First posted
- 2023-04-21
- Last updated
- 2023-06-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05824325. Inclusion in this directory is not an endorsement.